{
  "pmcid": "4846070",
  "sha256": "74d20db090eaf39fbaf94d7a22b386f2a0673671bb6950ed5a2e226429237ec5",
  "timestamp_utc": "2025-11-09T23:55:14.900102+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.544258206491843,
    "reading_ease": 32.030684027141035,
    "word_count": 287
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Oral Vinorelbine in Concurrent Chemoradiotherapy for Locally Advanced NSCLC"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A multicenter randomised controlled trial was conducted."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants aged 65 years or older with stage III NSCLC were eligible."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised participants to receive either oral vinorelbine with cisplatin and radiotherapy or standard cisplatin-based CCRT."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates the role of oral vinorelbine in concurrent chemoradiotherapy (CCRT) for elderly patients with locally advanced non-small cell lung cancer (NSCLC), aiming to improve efficacy and reduce toxicity compared to standard cisplatin-based regimens."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was overall response rate (ORR) at 3 months post-treatment."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was not applied to patients or clinicians, but outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 100 to the intervention group and 100 to the control group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 98 participants in the intervention group and 97 in the control group using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The ORR was 54% in the intervention group compared to 37% in the control group (p = 0.02)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events included grade 3 neutropenia in 9% of the intervention group and 4% in the control group."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "This study was funded by the National Cancer Institute."
      }
    },
    "total_score": 21,
    "max_score": 25
  }
}